Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Balstilimab + rHSC-DIPGVax + Zalifrelimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Balstilimab||AGEN-2034|AGEN2034||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086).|
|Zalifrelimab||AGEN-188AGEN1884|AGEN1884|UGN301|UGN 301|UGN-301||CTLA4 Antibody 28 Immune Checkpoint Inhibitor 146||Zalifrelimab (AGEN1884) is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (PMID: 31395100).|
|rHSC-DIPGVax||rHSC-DIPGVax is a peptide vaccine comprising 16 heat shock protein (HSP) neoepitopes associated with diffuse intrinsic pontine glioma and diffuse midline glioma, which potentially enhances cytotoxic T-lymphocyte (CTL) response against HSP neoepitope-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04943848||Phase I||rHSC-DIPGVax Balstilimab + rHSC-DIPGVax Balstilimab + rHSC-DIPGVax + Zalifrelimab||rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG||Recruiting||USA||0|